NCT01416259View on ClinicalTrials.gov

A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin

CompletedOBSERVATIONAL

Enrollment

56

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Healthy

Interventions

DRUG

Withdraw treatment

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

Sponsors

Lead Sponsor

Heron Therapeutics

All Listed Sponsors

lead

Heron Therapeutics

INDUSTRY